Peter R. Dottino, MD
Researchers must begin investigating more of the molecular phases of ovarian cancer in an effort to better understand and predict disease recurrence, according to Peter Dottino, MD.
on Treatment Options in Ovarian Cancer, Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discussed the utilization of molecular methods to identify ovarian cancer following treatment with chemotherapy, and how this type of research impacts the field going forward.
OncLive: What were the highlights of your presentation on ovarian cancer?
The information was on some of the molecular techniques that we have developed at Mount Sinai School of Medicine to be able to detect ovarian cancer after it has been treated with chemotherapy. What we did was go back into our biobank, which is approximately 10 years old, where we have preserved specimens and DNA from primary tumors and recurrent tumors, as well as second-look washings that were taken from patients at the time of laparoscopy.
These results just finished and have been submitted for publication.
What next steps would you like to take?
This was done with 10 patients—5 patients with positive second looks and 5 patients with negative second looks—so the next thing we need to do is validate this because it was a proof-of-principle study. Now, we will expand it to do it on more patients in the setting of a clinical trial. Then, based on the mutations that we find at the washings, we will try and use targeted therapies for those mutations so that we can prevent relapse.
Do you have targeted therapies in mind already that could be used?/span>
If you look at the 2 targeted therapies available for ovarian cancer today, it is going to be PARP inhibitors and VEGF inhibitors, but that doesn’t mean that there is not a whole series of ones that are coming along in phase I/II trials that will be potentially of use.
... to read the full story